What is Artiva Biotherapeutics, Inc. (ARTV)?

Artiva Biotherapeutics, Inc. (ARTV) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ARTV?

The current price of ARTV is $4.28. Prices are updated in real time on Stocks360.

What is ARTV's price-to-earnings (PE) ratio?

ARTV's trailing twelve-month PE ratio is -1.29, based on current price and earnings per share data available on Stocks360.

What is ARTV's market capitalization?

ARTV's market capitalization is $209,005,263.00, placing it in the small-cap tier.

Artiva Biotherapeutics, Inc. (ARTV)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$4.28

Market Cap

$209.01M

PE (TTM)

-1.29

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.41

Day Range

$4.22 – $4.39

52-wk Range

$2.96 – $14.53

Avg Volume

N/A

Volume

2.88M

Artiva Biotherapeutics, Inc. (ARTV) is a publicly traded company in the Healthcare sector. Latest price: $4.28. Market cap $209.01M. Trailing PE -1.29. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $4.39 2026-10-28 · $4.28 (-2.62%)

Earnings

Most Recent

Aug 6, 2026

EPS $-0.63 vs est. $-0.63

Missed by $0.00

Next Earnings

Nov 11, 2026

EPS estimate $-0.54

Proprietary Signals

Signal snapshot temporarily unavailable.

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.29×
P/S (TTM)	0.00×
P/B	0.48×
P/FCF (TTM)	-2.13×
EV / EBITDA	0.94×
EV / Sales	0.00×
Earnings Yield	-53.90%
Free Cash Flow Yield	-46.94%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$82.60M
Net Income (TTM)	-$112.66M
Free Cash Flow (TTM)	-$98.10M
Net Debt	-$291.61M
Working Capital	$337.69M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-53.86%
Return on Invested Capital	-26.91%